BSc (Hons); PhD
My current research focuses on understanding the mechanisms resulting in endocrine tumour formation and developing targeted therapies particularly for pancreatic, pituitary and parathyroid tumours (Thakker, Oxford). By identifying and understanding the underlying genetic defects, we aim to establish improved diagnostic tools and targeted therapies that can be translated into improved patient care. This has included characterizing models of hyperparathyroidism-jaw tumour syndrome and multiple endocrine neoplasia type 1 (MEN1), and use of a somatostatin analogue to treat pancreatic and pituitary tumours in in vivo models.
Prior to this I have studied the role of protein arginine methyltransferase 5 (PRMT5) in the growth of ovarian tumour cells (La Thangue, Oxford), and have a broad interest in the field of genetic therapies, particularly in regard to vector development for systemic administrations for the treatment of cancer which included developing targeted adenoviral vectors for the treatment of prostate cancer (Seymour, Oxford). I have also worked on the detection of the human papillomavirus type 16 E2 regulatory protein in cervical tissue (Maitland, York).
My PhD was performed at the University of Birmingham and involved the development of in-situ hybridisation for the cytogenetic analysis of Allium.
Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells
LINES K. et al, (2020), Endocrine-Related Cancer
Genetic approaches to metabolic bone diseases.
Hannan FM. et al, (2019), Br J Clin Pharmacol, 85, 1147 - 1160
Mice With a Brd4 Mutation Represent a New Model of Nephrocalcinosis.
Gorvin CM. et al, (2019), J Bone Miner Res
The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases.
Hannan FM. et al, (2018), Nat Rev Endocrinol, 15, 33 - 51
MiR-15a/miR-16-1 expression inversely correlates with cyclin D1 levels in Men1 pituitary NETs.
Lines KE. et al, (2018), J Endocrinol